subscribeSubscribe
Looking to expand Pyrukynd label, Agios treks toward PIII in sickle cell disease

Looking to expand Pyrukynd label, Agios treks toward PIII in sickle cell disease
Lei Lei Wu ENDPTS
26 Jun 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
Agios Presents PYRUKYND Data Demonstrating Sustained Clinical Benefit in Adults

Agios Presents PYRUKYND Data Demonstrating Sustained Clinical Benefit in Adults
GLOBENEWSWIRE
11 Dec 2022
Share Share
Agios Presents Updated PYRUKYND® Data Highlighting Long-term Safety Profile

Agios Presents Updated PYRUKYND® Data Highlighting Long-term Safety Profile
GLOBENEWSWIRE
10 Dec 2022
Share Share
Agios` Pyrukynd Receives Approval in Europe

Agios` Pyrukynd Receives Approval in Europe

EMA
05 Dec 2022
Share Share
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase

PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase
GLOBENEWSWIRE
10 Nov 2022
Share Share
Agios Appoints Cecilia Jones as Chief Financial Officer

Agios Appoints Cecilia Jones as Chief Financial Officer
PRESS RELEASE
19 Sep 2022
Share Share
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat)

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat)
GLOBENEWSWIRE
16 Sep 2022
Share Share
Agios Announces Publication of Phase 3 ACTIVATE-T Data

Agios Announces Publication of Phase 3 ACTIVATE-T Data
GLOBENEWSWIRE
18 Aug 2022
Share Share
Agios Announces Publication of Ph2 Data in The Lancet Safety of PYRUKYND®

Agios Announces Publication of Ph2 Data in The Lancet Safety of PYRUKYND®
GLOBENEWSWIRE
11 Aug 2022
Share Share